- Home
- ANGO vs AQST Comparison
ANGO vs AQST Comparison
Compare ANGO & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANGO
- AQST
- Stock Information
- Founded
- ANGO 1988
- AQST 2004
- Country
- ANGO United States
- AQST United States
- Employees
- ANGO N/A
- AQST N/A
- Industry
- ANGO Medical/Dental Instruments
- AQST Biotechnology: Pharmaceutical Preparations
- Sector
- ANGO Health Care
- AQST Health Care
- Exchange
- ANGO Nasdaq
- AQST Nasdaq
- Market Cap
- ANGO 400.8M
- AQST 390.4M
- IPO Year
- ANGO 2004
- AQST 2018
- Fundamental
- Price
- ANGO $8.56
- AQST $3.82
- Analyst Decision
- ANGO Strong Buy
- AQST Strong Buy
- Analyst Count
- ANGO 3
- AQST 7
- Target Price
- ANGO $19.00
- AQST $11.29
- AVG Volume (30 Days)
- ANGO 836.6K
- AQST 1.1M
- Earning Date
- ANGO 07-15-2025
- AQST 08-12-2025
- Dividend Yield
- ANGO N/A
- AQST N/A
- EPS Growth
- ANGO N/A
- AQST N/A
- EPS
- ANGO N/A
- AQST N/A
- Revenue
- ANGO $292,498,000.00
- AQST $54,228,000.00
- Revenue This Year
- ANGO $6.31
- AQST N/A
- Revenue Next Year
- ANGO $7.35
- AQST $51.62
- P/E Ratio
- ANGO N/A
- AQST N/A
- Revenue Growth
- ANGO N/A
- AQST 5.29
- 52 Week Low
- ANGO $5.83
- AQST $2.12
- 52 Week High
- ANGO $13.50
- AQST $5.80
- Technical
- Relative Strength Index (RSI)
- ANGO 35.78
- AQST 49.06
- Support Level
- ANGO $8.91
- AQST $3.85
- Resistance Level
- ANGO $9.32
- AQST $4.10
- Average True Range (ATR)
- ANGO 0.50
- AQST 0.23
- MACD
- ANGO -0.00
- AQST -0.07
- Stochastic Oscillator
- ANGO 7.44
- AQST 12.26
About ANGO AngioDynamics Inc.
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.